Covid-19: 200m doses of Pfizer vaccine to be distributed across EU by September

Newly released timetable confirms bloc will need other vaccines to speed up inoculations

The distribution of an initial 200 million doses of the Covid-19 vaccine developed by Pfizer and BioNTech across the EU will be completed by September, a spokesman for the European Commission said on Monday.

The protracted timetable, which was previously unknown, confirms that the bloc, with a population of 450 million, will need vaccines from other suppliers to speed up inoculations against the novel coronavirus.

Most EU countries began inoculating healthcare workers and vulnerable people on Sunday with the Pfizer vaccine, which is the only one so far authorised for Covid-19 in the 27-nation bloc, and requires a two-dose regimen.

“Distribution of the full 200 million doses is scheduled to be completed by September 2021,” the spokesman told Reuters in an emailed statement.

READ MORE

A spokesman for Pfizer declined to comment on specific schedules or whether the timeline indicated by the commission represented a delay in planned supplies, adding: “Our timelines are aspirational and can shift based on capacity and manufacturing timelines. These considerations will in turn refine supply projections and delivery schedules.”

Talks are under way on the delivery of a further 100 million doses which are optional under the contract sealed between the bloc and the two companies, the EU spokesman said, confirming an earlier report from Reuters.

The timetable for the additional doses is unclear.

The EU spokesman said most supply contracts agreed by the EU with Covid-19 vaccine makers foresee the majority of deliveries completed by the end of next year.

The EU has signed advance purchase agreements with Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, Moderna, Sanofi and CureVac for a total of nearly 2 billion vaccine doses.

The bloc’s drug regulator is to decide on the possible approval of the Moderna vaccine on January 6th, and has said that it could receive applications for approval from AstraZeneca and Johnson & Johnson in the first quarter of next year. – Reuters